Glucotrack, INC S-1 registration statements

Glucotrack, Inc. filed an S-1/A to register shares for resale under a new $20.0 million committed equity financing facility, while detailing significant progress in its implantable glucose monitor development and ongoing Nasdaq listing challenges.

Glucotrack, Inc. has entered into a $20 million committed equity financing agreement with Sixth Borough Capital Fund, LP, while progressing its implantable continuous blood glucose monitor through human trials and addressing Nasdaq listing compliance.

GlucoTrack, Inc. files an amendment to its Form S-1 registration statement, primarily to include an updated legal opinion regarding the shares, warrants, and related securities being offered.

Glucotrack aims to raise up to $30 million by offering common stock, pre-funded warrants, and common stock purchase warrants.

Glucotrack, Inc. announces a proposed offering of common stock, pre-funded warrants, and common warrants to raise capital for general corporate purposes.

Glucotrack, Inc. is offering shares of common stock along with Series A and Series B warrants, and pre-funded warrants, aiming to raise capital for general corporate purposes, including clinical trials and operating expenses.

Glucotrack, Inc. files for a public offering of common stock and warrants to fund the development of its implantable continuous glucose monitor (CGM) and for general corporate purposes.